系统综述:糖组学作为肝细胞癌的诊断标志物
该研究综合检索多个数据库至2023年8月17日,共纳入48篇文章,评估血清N-糖组学作为肝细胞癌诊断标志物的潜力。研究发现岩藻糖基化和分支水平升高是肝细胞癌患者糖蛋白最常见的翻译后修饰,基于糖组学的标志物可能有助于早期肝细胞癌诊断,部分算法达到AUC 0.92-0.97,但这些结果基于样本量有限的单项研究,尚需验证。
要点
- 血清N-糖组学改变以岩藻糖基化和分支水平升高为特征,有潜力作为肝细胞癌诊断标志物。
- 部分糖组学算法诊断早期肝细胞癌的AUC达0.92-0.97,但基于样本量有限的单项研究,需验证。
- 临床实施前需优化研究设计、患者选择和分析技术。
核心结论
- 血清N-糖组学改变以岩藻糖基化和分支水平升高为特征,有潜力作为肝细胞癌诊断标志物。
- 临床实施前需优化研究设计、患者选择和分析技术。
研究设计与样本
- 系统综述,检索PubMed、EMBASE、Web of Science和Scopus至2023年8月17日。
- 共纳入48篇文章,其中11篇评估全血清N-糖组学用于肝细胞癌诊断,其余关注特定蛋白糖型或蛋白水平。
- 研究筛选、数据提取和质量评估由两名独立评审员完成。
主要发现
- 最常研究的特定蛋白包括触珠蛋白、甲胎蛋白(AFP)、激肽原(Kin)、α-1-抗胰蛋白酶和高尔基体蛋白73(GP73)。
- 与对照相比,肝细胞癌患者糖蛋白最常见的翻译后修饰为岩藻糖基化和分支水平升高。
- 基于糖组学的标志物可能为早期肝细胞癌诊断提供临床获益,多个算法AUC达0.92-0.97。
关键数值与推荐
- 部分糖组学算法诊断早期肝细胞癌的AUC为0.92-0.97,但基于样本量有限的单项研究,应予以验证。
临床怎么用
- 原文未据此给出推荐。
局限性
- 部分算法AUC 0.92-0.97的结果基于样本量有限的单项研究,应予以验证。
- 临床实施前需优化研究设计、患者选择和分析技术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with one of the highest cancer-related mortality rates worldwide. Early diagnosis is crucial for improving the therapeutic options and reducing the disease-related mortality. AIM: To investigate serum N-glycomics as diagnostic markers for HCC. METHODS: We performed a comprehensive search in PubMed, EMBASE, Web of Science and Scopus through August 17, 2023. Eligible studies assessed the potential use of serum N-glycomics as diagnostic biomarkers for HCC. Study selection, data extraction and quality assessment were performed by two independent reviewers. RESULTS: Of the 48 articles included, 11 evaluated the utility of N-glycomics for the diagnosis of HCC in whole serum while the remaining articles focused on specific protein glycoforms or protein levels. Of these specific proteins, haptoglobin, alpha-fetoprotein (AFP), kininogen (Kin), α-1-antitrypsin and Golgi protein 73 (GP73) were the most frequently studied. Increased levels of fucosylation and branching presented as the most prevalent post-translational modifications of glycoproteins in patients with HCC compared to controls. Notably, glycomics-based biomarkers may provide a clinical benefit for the diagnosis of early HCC, as several algorithms achieved AUCs between 0.92-0.97. However, these were based on single studies with limited sample sizes and should therefore be validated. CONCLUSIONS: Alterations in serum N-glycomics, characterised by increased levels of fucosylation and branching, have potential as diagnostic biomarkers for HCC. Optimisation of study design, patient selection and analysing techniques are needed before clinical implementation will be possible.
引用
- Butaye E, Somers N, Grossar L, et al. Systematic review: Glycomics as diagnostic markers for hepatocellular carcinoma. Aliment Pharmacol Ther. 2023. PMID: 37877758. doi:10.1111/apt.17748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。